GUANGZHOU – November 07, 2026 -- POMDOCTOR LIMITED (NASDAQ: POM) has regained compliance with Nasdaq's $1.00 minimum bid price requirement, removing the immediate threat of delisting for its Class A ordinary shares.
The company received a compliance letter from The Nasdaq Stock Market LLC on November 5, 2026, confirming it meets Listing Rule 5450(a)(1). The Nasdaq Hearings Panel hearing originally scheduled for November 12, 2026 has been cancelled as a result.
Nasdaq issued a staff delisting determination on October 6 after 30 straight business days below $1.00
The compliance confirmation follows a staff delisting determination letter dated October 6, 2026. Nasdaq had found that the closing bid price of Pomdoctor's securities was below $1.00 per share for 30 consecutive business days.
Class A shares remain listed and traded under the ticker POM
Nasdaq's confirmation means the Class A ordinary shares continue to trade on the exchange under the symbol "POM." The company describes itself as a digital healthcare business focused on AI-enabled healthcare solutions and predictive healthcare capabilities.